2013
DOI: 10.1038/nature12118
|View full text |Cite
|
Sign up to set email alerts
|

The TLR4 antagonist Eritoran protects mice from lethal influenza infection

Abstract: Summary There is pressing need to develop alternatives to annual influenza vaccines and antiviral agents licensed for mitigating influenza infection. Previous studies reported that acute lung injury (ALI) caused by chemical or microbial insults is secondary to generation of host-derived, oxidized phospholipid that potently stimulates Toll-like Receptor 4 (TLR4)-dependent inflammation1. Subsequently, we reported that TLR4−/− mice are highly refractory to influenza-induced lethality2, and hypothesized that thera… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

21
421
0
2

Year Published

2013
2013
2019
2019

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 375 publications
(451 citation statements)
references
References 31 publications
21
421
0
2
Order By: Relevance
“…Such therapeutic strategies could interfere with host signalling pathways necessary for viral replication, inhibit exaggerated inflammation, or promote tissue regeneration in an effort to dampen organ dysfunction and injury [196]. Strategies that limit immune responses, for example, by inhibiting the activation of TLR4 by oxidised phospholipids [80,197], targeting the S1P receptor or the angiotensin/ACE system [124,126,197,198] or even attenuating the production of type I IFNs [107], have been shown to reduce the severity of IAV-induced mortality in murine models. Similarly, strategies that promote immune resolution or tissue regeneration, e.g.…”
Section: Discussionmentioning
confidence: 99%
“…Such therapeutic strategies could interfere with host signalling pathways necessary for viral replication, inhibit exaggerated inflammation, or promote tissue regeneration in an effort to dampen organ dysfunction and injury [196]. Strategies that limit immune responses, for example, by inhibiting the activation of TLR4 by oxidised phospholipids [80,197], targeting the S1P receptor or the angiotensin/ACE system [124,126,197,198] or even attenuating the production of type I IFNs [107], have been shown to reduce the severity of IAV-induced mortality in murine models. Similarly, strategies that promote immune resolution or tissue regeneration, e.g.…”
Section: Discussionmentioning
confidence: 99%
“…competitively inhibits binding of lipid A to MD2 and thereby inhibits downstream signaling (26). Eritoran was also shown to bind to CD14 and block the transfer of lipid A to MD2 (27). Eritoran blocks LPS-induced MyD88-and TRIF-dependent cytokine production in human and murine macrophages (28).…”
Section: Resultsmentioning
confidence: 99%
“…This suggests that at this time, general or specific interventions can be implemented to avert SIRS. Although targeted therapies such as specific TLR4 inhibitors did not alter outcomes in patients with severe sepsis, 26,27 this may be due to the fact that patients were already critically unwell and at advanced stages of SIRS when given a TLR4 antagonist. We hypothesise that treating patients with TLR4 inhibitors or agents that impair signalling through TLR5 or NF-kB may provide therapeutic benefit before the clinical manifestations of SIRS or sepsis become apparent.…”
Section: Patients Who Develop Sirs Have a Greater Proportion Of Cd14mentioning
confidence: 99%